These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18702995)

  • 1. Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis.
    Martin R
    Lancet Neurol; 2008 Sep; 7(9):765-6. PubMed ID: 18702995
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade.
    Schurich A; Raine C; Morris V; Ciurtin C
    Rheumatology (Oxford); 2018 Feb; 57(2):246-254. PubMed ID: 28541488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
    Gandhi M; Alwawi E; Gordon KB
    Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
    Taoufik E; Tseveleki V; Euagelidou M; Emmanouil M; Voulgari-Kokota A; Haralambous S; Probert L
    Neurodegener Dis; 2008; 5(1):32-7. PubMed ID: 18075273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab poised to enter the psoriasis market.
    Schmidt C
    Nat Biotechnol; 2008 Dec; 26(12):1317-8. PubMed ID: 19060851
    [No Abstract]   [Full Text] [Related]  

  • 6. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM; Constantinescu CS; Raychaudhuri A; Kim L; Fidelus-Gort R; Kasper LH;
    Lancet Neurol; 2008 Sep; 7(9):796-804. PubMed ID: 18703004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model.
    Konoeda F; Shichita T; Yoshida H; Sugiyama Y; Muto G; Hasegawa E; Morita R; Suzuki N; Yoshimura A
    Biochem Biophys Res Commun; 2010 Nov; 402(3):500-6. PubMed ID: 20965150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
    Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
    Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could anti IL12/23 therapy replace anti-TNF biologics?
    Ionescu MA; Lipozencić J
    Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune diseases. The B cell slayer.
    Matthews R
    Science; 2007 Nov; 318(5854):1232-3. PubMed ID: 18033858
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic antibodies in multiple sclerosis.
    Goebels N; Becher B
    Neurodegener Dis; 2008; 5(1):5-7. PubMed ID: 18075268
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S; Berger JR
    J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract]   [Full Text] [Related]  

  • 13. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
    Longbrake EE; Racke MK
    Expert Rev Neurother; 2009 Mar; 9(3):319-21. PubMed ID: 19271940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis.
    't Hart BA; Hintzen RQ; Laman JD
    Neurodegener Dis; 2008; 5(1):38-52. PubMed ID: 18075274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
    [No Abstract]   [Full Text] [Related]  

  • 16. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
    Griffiths CE; Girolomoni G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis: pathophysiology revisited.
    Sorensen PS
    Lancet Neurol; 2005 Jan; 4(1):9-10. PubMed ID: 15620850
    [No Abstract]   [Full Text] [Related]  

  • 18. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
    Mortel MR; Emer J
    J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroinflammatory diseases with a focus on multiple sclerosis - an overview].
    Hohlfeld R
    Drug Res (Stuttg); 2013 Nov; 63 Suppl 1():S3-4. PubMed ID: 24242037
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC; Hartung HP
    Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.